Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E9.96 EPS (ttm)23.33 Insider Own0.10% Shs Outstand194.70M Perf Week-0.49%
Market Cap45.26B Forward P/E7.55 EPS next Y30.78 Insider Trans- Shs Float189.96M Perf Month-1.06%
Income4.69B PEG1.88 EPS next Q7.53 Inst Own92.40% Short Float1.51% Perf Quarter1.60%
Sales13.81B P/S3.28 EPS this Y24.50% Inst Trans-0.08% Short Ratio1.65 Perf Half Y-31.10%
Book/sh70.35 P/B3.30 EPS next Y3.80% ROA18.40% Target Price253.00 Perf Year-35.08%
Cash/sh20.08 P/C11.58 EPS next 5Y5.29% ROE35.30% 52W Range216.12 - 388.67 Perf YTD-22.74%
Dividend- P/FCF7.59 EPS past 5Y22.70% ROI23.60% 52W High-40.19% Beta0.99
Dividend %- Quick Ratio2.60 Sales past 5Y14.20% Gross Margin85.70% 52W Low7.57% ATR4.48
Employees7800 Current Ratio2.80 Sales Q/Q11.50% Oper. Margin42.40% RSI (14)48.26 Volatility1.51% 2.03%
OptionableYes Debt/Eq0.00 EPS Q/Q29.10% Profit Margin33.80% Rel Volume0.71 Prev Close231.27
ShortableYes LT Debt/Eq0.43 EarningsJul 23 BMO Payout0.00% Avg Volume1.74M Price232.48
Recom2.90 SMA20-0.86% SMA500.68% SMA200-18.10% Volume1,275,996 Change0.52%
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Jul-23-19 07:29AM  US STOCKS-Futures rise after better-than-expected earnings Reuters
07:27AM  Biogen Earnings Crush Views, But Biotech Giant Little Changed Investor's Business Daily
07:11AM  Biotech group Biogen boosted by sales of key drugs Financial Times
06:58AM  UPDATE 1-Biogen profit rises 72% on multiple sclerosis therapy sales Reuters
06:45AM  Biogen's stock jumps after big earnings beat, raised outlook MarketWatch
06:39AM  Biogen profit rises 72% Reuters
03:39AM  Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost
02:47AM  Biogen Earnings, Revenue Beat in Q2
Jul-22-19 04:09PM  Biogen Earnings: Here's What Investors Are Hoping To See In Report Investor's Business Daily
01:58PM  MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock InvestorPlace
09:32AM  Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Heres what to expect MarketWatch
Jul-20-19 09:53AM  The Week Ahead In Biotech: Pharma Earnings Pick Up Pace Benzinga
Jul-19-19 09:35AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks
Jul-17-19 03:22PM  The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On Motley Fool
Jul-16-19 02:14PM  Eisai boosts focus on Alzheimer's with new research facility, funding American City Business Journals
10:31AM  Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jul-13-19 10:26AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
07:26AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-12-19 10:24AM  Amgen & Novartis' Alzheimer Studies End in Another Failure Zacks
Jul-11-19 04:51PM  Amgen and Novartis drop Alzheimer's-prevention study after patients worsened MarketWatch
07:24AM  2 Falling Pharma Stocks Whose Star May Rise in 2019 TipRanks
Jul-10-19 08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
Jul-09-19 03:55PM  Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads Yahoo Finance Video
03:02PM  Top Analyst Reports for Boeing, 3M & U.S. Bancorp Zacks
Jul-08-19 02:36PM  Skyhawk Therapeutics adds Merck to nest of drug partners American City Business Journals
11:06AM  Why Biogen Stock Has Plummeted in 2019 Motley Fool
10:10AM  Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks
Jul-05-19 12:11PM  Biogen Revenue Has the Potential to Meet Wall Street Expectations, Analyst Says
06:43AM  Is Biogen Inc.'s (NASDAQ:BIIB) ROE Of 34% Impressive? Simply Wall St.
Jul-03-19 01:59PM  Here are the Mass. firms with the highest and lowest profits per employee American City Business Journals
01:49PM  Why These 4 Biotech Leaders Could Rebound On Strong Earnings Investor's Business Daily
12:57PM  2 Health Care Companies to Consider for the 2nd Half of the Year
Jul-01-19 09:25AM  Atara Reports Initial Data for Multiple Sclerosis Candidate Zacks
07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients PR Newswire
07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients GlobeNewswire
Jun-30-19 08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-29-19 07:44AM  Here are the stock markets winners and losers in the first half of 2019 MarketWatch
04:00AM  Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy GlobeNewswire
Jun-28-19 10:55AM  Options Bulls Continue to Blitz Embattled Biogen Stock Schaeffer's Investment Research
09:40AM  Biogen Drops After Piper Jaffray Downgrade, Price Target Cut
09:01AM  Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition
Jun-27-19 04:38PM  Biogen Drug Gets a Thumbs-Down From Neurologist
Jun-26-19 10:06AM  Biogen Could Rally in the Weeks Ahead
08:58AM  AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
Jun-25-19 11:02AM  The 10 Biggest Biotech Stocks Motley Fool
09:07AM  5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB) Zacks
08:40AM  The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon Zacks
Jun-24-19 03:37PM  Top Stock Reports for Union Pacific, NextEra & Biogen Zacks
Jun-20-19 11:48AM  Biotech companies dominate fastest-growing public companies list again American City Business Journals
Jun-19-19 11:49AM  3 Large-Cap Biotech Stocks to Buy for Massive Gains InvestorPlace
Jun-18-19 08:00AM  3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal Motley Fool
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 09:51AM  AstraZeneca Gives Detailed Data From Calquence Leukemia Study Zacks
Jun-14-19 12:03PM  Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures Investor's Business Daily
Jun-13-19 05:50PM  Biogen (BIIB) Gains But Lags Market: What You Should Know Zacks
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
06:00AM  Ontario grants broader access to SPINRAZA (nusinersen) for patients living with spinal muscular atrophy (SMA) CNW Group
Jun-12-19 12:49PM  Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings Simply Wall St.
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
Jun-11-19 07:05PM  Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 GlobeNewswire
11:26AM  Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace
Jun-10-19 04:40PM  Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey
Jun-07-19 05:50PM  Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
05:00PM  Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks
05:41AM  Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million GlobeNewswire
Jun-06-19 04:19PM  Will This Downbeat Biotech Regain Investor Trust With ALS Drugs? Investor's Business Daily
10:38AM  Biogen Stock Is Slipping Because Investors Dont Buy Its News on Lou Gehrigs Disease
May-31-19 09:07AM  Biogen Reports Interim Phase III Data on Diroximel Fumarate Zacks
08:11AM  Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs Zacks
May-30-19 11:02AM  PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts Zacks
07:30AM  New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
07:15AM  The Case for a Biogen Acquisition and 3 Potential Targets
May-29-19 05:50PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
08:59AM  Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma Zacks
May-28-19 07:00AM  Primecaps Golden Lineup: Its Six Funds Come in Pairs Morningstar
May-27-19 11:10AM  Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily
06:48AM  Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems Zacks
May-24-19 07:39PM  Novartis $2 million gene therapy for rare disorder is world's most expensive drug Reuters
07:39PM  For Anderson family, an early bet on SMA gene therapy Reuters
01:30PM  Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval American City Business Journals
10:55AM  Biogen Stock One of the Best to Own Next Week Schaeffer's Investment Research
09:31AM  Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound? Zacks
May-23-19 05:27PM  Preclinical biotech Stoke Therapeutics plans $86M IPO American City Business Journals
03:53PM  Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY) Zacks
11:44AM  The Patient View: Biogen Alzheimer's Trial Participant Jeff Borghoff at Healthy Returns CNBC Videos
09:17AM  The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific Zacks
09:06AM  Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire
07:10AM  The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks CNBC
May-22-19 04:30PM  3 Tech Stocks for Growth Investors to Buy Right Now Zacks
02:43PM  Top Research Reports for Chubb, Las Vegas Sands & Biogen Zacks
11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
05:35AM  The Best and Worst Big Biotech Stocks, According to One Analyst
May-21-19 04:55PM  We don't yet have the technology to cure Alzheimer's, health-care investor says CNBC
03:00PM  Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending Insider Monkey
May-20-19 04:30PM  Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer Investor's Business Daily
07:40AM  Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital MarketWatch
07:30AM  Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation GlobeNewswire
May-17-19 05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
May-16-19 02:54PM  Wayfair cracks Fortune 500 list, joins 15 other Mass. companies American City Business Journals
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM